{"filing":{"accession_number":"0000879169-26-000040","cik":"0000879169","ticker":"INCY","company_name":"INCYTE CORP","form":"8-K","filing_date":"2026-06-08","report_date":null,"primary_document":"incy-20260608.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/879169/000087916926000040/incy-20260608.htm"},"events":[{"id":6105,"run_id":5360,"accession_number":"0000879169-26-000040","anchor_item_number":"8.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"summary":"Incyte Corporation announced entry into a definitive agreement to acquire Vega Therapeutics, a material acquisition transaction. Although disclosed under Item 8.01 (Other Events), the substance is a binding M\u0026A commitment that would materially affect the registrant's business and financial position, warranting classification as ma_activity rather than a routine administrative disclosure.","company_name":"INCYTE CORP","ticker":"INCY","filing_date":"2026-06-08","form":"8-K","submitted_at":null,"items":[{"id":5039,"accession_number":"0000879169-26-000040","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Incyte Corporation announced entry into a definitive agreement to acquire Vega Therapeutics, a material acquisition transaction. Although disclosed under Item 8.01 (Other Events), the substance is a binding M\u0026A commitment that would materially affect the registrant's business and financial position, warranting classification as ma_activity rather than a routine administrative disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T11:07:05.500698+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":5039,"accession_number":"0000879169-26-000040","item_number":"8.01","item_title":"Other Events.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Incyte Corporation announced entry into a definitive agreement to acquire Vega Therapeutics, a material acquisition transaction. Although disclosed under Item 8.01 (Other Events), the substance is a binding M\u0026A commitment that would materially affect the registrant's business and financial position, warranting classification as ma_activity rather than a routine administrative disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-08T11:07:05.500698+00:00","company_name":"INCYTE CORP","ticker":"INCY","filing_date":"2026-06-08"}]}